Schrodinger Inc
$ 18.16
1.97%
07 Aug - close price
- Market Cap 1,358,470,000 USD
- Current Price $ 18.16
- High / Low $ 18.85 / 17.48
- Stock P/E N/A
- Book Value 4.21
- EPS -0.74
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.16 %
- 52 Week High 23.02
- 52 Week Low 10.95
About
Schrdinger, Inc. provides a physics-based software platform that enables the discovery of novel molecules for drug development and material applications. The company is headquartered in New York, New York.
Analyst Target Price
$20.57
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-05 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-12 | 2024-07-31 | 2024-05-01 | 2024-02-28 | 2023-11-01 |
| Reported EPS | 0.08 | -0.62 | -0.1802 | -0.45 | -0.65 | -0.64 | -0.24 | -0.87 | -0.74 | -0.76 | -0.41 | -0.7 |
| Estimated EPS | -0.6 | -0.57 | -0.195 | -0.75 | -0.64 | -0.81 | -0.38 | -0.63 | -0.89 | -0.74 | -0.38 | -0.69 |
| Surprise | 0.68 | -0.05 | 0.0148 | 0.3 | -0.01 | 0.17 | 0.14 | -0.24 | 0.15 | -0.02 | -0.03 | -0.01 |
| Surprise Percentage | 113.3333% | -8.7719% | 7.5897% | 40% | -1.5625% | 20.9877% | 36.8421% | -38.0952% | 16.8539% | -2.7027% | -7.8947% | -1.4493% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SDGR
2026-08-06 18:41:12
TD Cowen has reiterated its Buy rating for Schrodinger (SDGR.US), maintaining a target price of $20. This indicates the firm's continued confidence in the company's financial prospects and stock performance.
2026-08-06 06:12:34
Schrödinger, Inc. reported strong Q2 2026 results with a shift to profitability and a significant expansion of its AI co-scientist collaboration with Bristol Myers Squibb. This deal, involving the new agentic AI Bunsen, reinforces the company's AI-driven growth ambitions and its computational platform's growing adoption within major pharmaceutical companies. While supporting the near-term AI software catalyst, investors should remain aware of potential concentration in software revenue and margin pressures.
2026-08-06 04:41:12
Schrödinger (Nasdaq: SDGR) announced its second quarter 2026 financial results, reporting ACV of $29.6 million, a 27% increase year-over-year, and total revenue of $58.9 million, an 8% increase. The company also launched an early access version of Bunsen, its new agentic AI co-scientist for molecular discovery, and provided financial guidance for the full fiscal year 2026, expecting ACV to range from $218 million to $228 million.
2026-08-06 02:12:34
Schrodinger (NASDAQ:SDGR) announced quarterly earnings results, significantly surpassing analyst expectations with an EPS of $0.08 against an estimated loss of $0.41, and revenue of $58.89 million, exceeding estimates of $47.19 million. The company's software annual contract value grew 27%, driven by large pharmaceutical, biotech, and materials-science customers, and it launched its Bunsen AI co-scientist while also raising its 2026 drug-discovery revenue outlook to $65 million-$75 million. Despite the positive results, analysts maintain an average "Hold" rating with a $20.25 price target.
2026-08-05 20:35:00
Schrodinger, Inc. (SDGR) reported Q2 earnings of $0.08 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.6 per share, and revenues of $58.89 million, surpassing estimates by 15.58%. Despite this strong quarterly performance, the company's shares have underperformed the S&P 500 year-to-date, and it currently holds a Zacks Rank #3 (Hold), indicating an expected performance in line with the market.
2026-08-05 20:12:34
Schrödinger (SDGR) significantly exceeded Q2 2026 earnings and revenue forecasts, reporting a profit of $0.08 per share against an expected loss and revenue of $58.9 million, above estimates. The company saw a 27% increase in annual contract value, driven by strong demand for its software platform and drug discovery work, including new products like Bunsen and Predictive Tox. Management raised its full-year drug discovery revenue guidance and shares rose after the announcement, reflecting investor approval despite continued volatility and a current "FAIR" financial health rating from InvestingPro.
